Hypertension, Dyslipidemia, and Insulin Resistance in Patients With Diabetes Mellitus or the Cardiometabolic Syndrome: Benefits of Vasodilating β‐Blockers
View Full Paper
Ask AI
Bookmark
Share
Key result
Vasodilating β-blockers reduce peripheral vascular resistance without adversely affecting insulin sensitivity, glycemic control, or lipid profiles compared with traditional β-blockers.
Why the study?
Do vasodilating beta-blockers improve metabolic profiles compared to traditional beta-blockers in patients with hypertension and diabetes or cardiometabolic syndrome?
Population
Patients with hypertension and coexisting diabetes mellitus or cardiometabolic syndrome
Comparison
Vasodilating beta-blockers vs Traditional beta-blockers
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
β-Blocker metabolic effects vary by agent in diabetic hypertension; leaves open agent-specific selection pending randomized confirmation.
Structured PICO
Do vasodilating beta-blockers improve metabolic profiles compared to traditional beta-blockers in patients with hypertension and diabetes or cardiometabolic syndrome?
P
Population
Patients with hypertension and coexisting diabetes mellitus or cardiometabolic syndrome
I
Intervention
Vasodilating beta-blockers (e.g., nebivolol, carvedilol, labetalol)
C
Comparator
Traditional beta-blockers (e.g., atenolol, metoprolol)
O
Outcome
Effects on glucose and lipid metabolism (including insulin resistance, glycemic control, dyslipidemia, and new-onset diabetes)surrogate
Vasodilating beta-blockers offer a favorable metabolic profile compared to traditional beta-blockers, making them a preferred antihypertensive option for high-risk patients with diabetes or cardiometabolic syndrome.
Limitations
- Clinical outcome data for beta-blockers are derived primarily from atenolol, making it unclear whether conclusions can be generalized to all beta-blockers.
Cite This Study
Prakash Deedwania (2010) conducted a review in Hypertension, Diabetes Mellitus, Cardiometabolic Syndrome. Vasodilating β-blockers vs. Traditional β-blockers was evaluated. Vasodilating β-blockers reduce peripheral vascular resistance without adversely affecting insulin sensitivity, glycemic control, or lipid profiles compared with traditional β-blockers.
Topics
View Full Paper
Ask AI
Bookmark
Share